Physician profile
Adam Highley
NPI 1316234131
$15,303.12
in general payments reported to CMS, 2019-2025
20 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $74.10 · 2022: $47.01 · 2023: $13K · 2024: $468 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Food and Beverage: $1,036 · Travel and Lodging: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $12,000.00 |
| Food and Beverage | $1,036.19 |
| Travel and Lodging | $906.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,258.61 | 2023-2025 | Da Vinci Surgical System, Ion |
| Veran Medical Technologies, INC. | $1,096.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.51 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $191.82 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Merck Sharp & Dohme LLC | $93.74 | 2023-2025 | Winrevair |
| Grifols USA, LLC | $80.09 | 2019-2023 | Prolastin-C Liquid |
| Abiomed | $63.95 | 2024 | Impella |
| Ambu INC. | $58.98 | 2023-2024 | |
| Glaxosmithkline, LLC. | $33.31 | 2024-2025 | Nucala |
| Electromed, INC. | $31.06 | 2019-2022 | |
| Genzyme Corporation | $30.82 | 2024-2025 | |
| Amgen INC. | $29.45 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $28.19 | 2022-2023 | Dupixent |
| Pulmonx Corporation | $19.72 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Jazz Pharmaceuticals INC. | $17.47 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $16.94 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $16.26 | 2024 | Opsumit, Uptravi |
| Avadel Cns Pharmaceuticals, LLC | $15.68 | 2024 | Lumryz |
| Bayer Healthcare Pharmaceuticals INC. | $15.07 | 2022 | |
| Gilead Sciences, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Highley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.